278 related articles for article (PubMed ID: 29362903)
1. Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach.
Candelaria M; Gonzalez D; Fernández Gómez FJ; Paravisini A; Del Campo García A; Pérez L; Miguel-Lillo B; Millán S
Cancer Chemother Pharmacol; 2018 Mar; 81(3):515-527. PubMed ID: 29362903
[TBL] [Abstract][Full Text] [Related]
2. Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study.
Candelaria M; González DE; Delamain MT; Bär DO; Beniwal SK; Dasappa L; Flores DH; Querol J; Guan TS; Lipatov ON; Volodicheva EM; Patel M; Safaee Nodehi SR; Fogliatto L; Paravisini A; Perez Diaz L;
Leuk Lymphoma; 2019 Dec; 60(14):3375-3385. PubMed ID: 31272251
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma.
Gota V; Karanam A; Rath S; Yadav A; Tembhare P; Subramanian P; Sengar M; Nair R; Menon H
Cancer Chemother Pharmacol; 2016 Aug; 78(2):353-9. PubMed ID: 27329361
[TBL] [Abstract][Full Text] [Related]
4. A Randomized, Double-Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis.
Burmester G; Chien D; Chow V; Gessner M; Pan J; Cohen S
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):1003-1014. PubMed ID: 32627420
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
Chen X; Li C; Ewesuedo R; Yin D
Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
[TBL] [Abstract][Full Text] [Related]
6. A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis.
Cohen S; Emery P; Greenwald M; Yin D; Becker JC; Melia LA; Li R; Gumbiner B; Thomas D; Spencer-Green G; Meng X
Br J Clin Pharmacol; 2016 Jul; 82(1):129-38. PubMed ID: 26909489
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma.
Shemesh CS; Agarwal P; Lu T; Lee C; Dere RC; Li X; Li C; Jin JY; Girish S; Miles D; Lu D
Cancer Chemother Pharmacol; 2020 May; 85(5):831-842. PubMed ID: 32222808
[TBL] [Abstract][Full Text] [Related]
8. Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma.
Viswabandya A; Shah S; Mukhopadhyay A; Nagarkar RV; Batra SS; Lopez-Lazaro L; Kankanwadi S; Srivastava A
J Glob Oncol; 2019 Nov; 5():1-13. PubMed ID: 31809224
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Safety and Effectiveness of Rituximab Biosimilar RTXM83: A Retrospective Extension Study in Brazilian Patients with Diffuse Large B-Cell Lymphoma.
Delamain MT; Cardoso ACF; Pericole FV; da Silva Araújo SS; Fogliatto L; Higashi M; Pereira J; da Silva RL; Werutsky G; de Paulo Giacon Radtke P; Salvino MA; Castilho V
Oncol Ther; 2024 Jun; ():. PubMed ID: 38829416
[TBL] [Abstract][Full Text] [Related]
10. A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab.
Esteva FJ; Stebbing J; Wood-Horrall RN; Winkle PJ; Lee SY; Lee SJ
Cancer Chemother Pharmacol; 2018 Mar; 81(3):505-514. PubMed ID: 29330636
[TBL] [Abstract][Full Text] [Related]
11. GP2013: A Rituximab Biosimilar.
Blair HA
BioDrugs; 2017 Oct; 31(5):465-468. PubMed ID: 28921160
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study.
Haridas VM; Katta R; Nalawade A; Kharkar S; Zhdan V; Garmish O; Lopez-Lazaro L; Batra SS; Kankanwadi S
BioDrugs; 2020 Apr; 34(2):183-196. PubMed ID: 32052313
[TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP.
Baudry E; Huguet S; Couderc AL; Chaibi P; Bret F; Verny C; Weill S; Madar O; Urien S; Rezai K
Cancer Chemother Pharmacol; 2019 Apr; 83(4):775-785. PubMed ID: 30689002
[TBL] [Abstract][Full Text] [Related]
14. Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India.
Patel A; Bhatt N; Prakash SS; Biswas G; Nagarkar R; Roy B; Samal P; Agrawal N; Meshram S; Kaushal A; Satheesh CT; Wategaonkar R; Thiagarajan KV; Jain K; Vijayaveeran P; Mukherjee K; Singh K; Patil T; Jain A; Dolai TK; Jain M; Hingmire S; Gupta TC; Lakshmaiah KC; Rajamanickam D; Nemade B; Goyal V; Mahato P; Mendiratta SK; Doshi M
Cancer Chemother Pharmacol; 2023 Jun; 91(6):457-468. PubMed ID: 37093266
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20
Jiang B; Ke X; Zhang Q; Xu W; Su H; Huang J; Zhang M; Wang H; Jin C; Zhu J; Liu L; Cai Z; Zhao X; Zhou J; Zhang X; Liu J; Zhou H; Yu J; Sun X; Qi J; Qiu L
Sci Rep; 2020 Jul; 10(1):11676. PubMed ID: 32669656
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome.
Rozman S; Grabnar I; Novaković S; Mrhar A; Jezeršek Novaković B
Br J Clin Pharmacol; 2017 Aug; 83(8):1782-1790. PubMed ID: 28239897
[TBL] [Abstract][Full Text] [Related]
18. A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera
Sharman JP; Liberati AM; Ishizawa K; Khan T; Robbins J; Alcasid A; Rosenberg JA; Aurer I
BioDrugs; 2020 Apr; 34(2):171-181. PubMed ID: 31820339
[TBL] [Abstract][Full Text] [Related]
19. A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin
Wynne C; Schwabe C; Batra SS; Lopez-Lazaro L; Kankanwadi S
Br J Clin Pharmacol; 2018 Oct; 84(10):2352-2364. PubMed ID: 29943831
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome of diffuse large B-cell lymphoma: Impact of biosimilar rituximab and radiation.
Ganesan P; Sagar TG; Kannan K; Radhakrishnan V; Rajaraman S; John A; Sundersingh S; Mahajan V; Ganesan TS
Indian J Cancer; 2017; 54(2):430-435. PubMed ID: 29469072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
